Syndax Pharmaceuticals Statistics
Share Statistics
Syndax Pharmaceuticals has 86.05M
shares outstanding. The number of shares has increased by 1.22%
in one year.
| Shares Outstanding | 86.05M |
| Shares Change (YoY) | 1.22% |
| Shares Change (QoQ) | 0.78% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,500 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 21.66M, so 25.17% of the outstanding
shares have been sold short.
| Short Interest | 21.66M |
| Short % of Shares Out | 25.17% |
| Short % of Float | 28.43% |
| Short Ratio (days to cover) | 13.47 |
Valuation Ratios
The PE ratio is -3.55 and the forward
PE ratio is -3.91.
Syndax Pharmaceuticals's PEG ratio is
-0.14.
| PE Ratio | -3.55 |
| Forward PE | -3.91 |
| PS Ratio | 47.8 |
| Forward PS | 1.4 |
| PB Ratio | 3.93 |
| P/FCF Ratio | -4.12 |
| PEG Ratio | -0.14 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Syndax Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.82,
with a Debt / Equity ratio of 1.2.
| Current Ratio | 5.82 |
| Quick Ratio | 5.82 |
| Debt / Equity | 1.2 |
| Debt / EBITDA | -1.1 |
| Debt / FCF | -1.26 |
| Interest Coverage | -68.91 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $87,703.7 |
| Profits Per Employee | $-1,180,585.19 |
| Employee Count | 270 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 2.26 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -52.95% in the
last 52 weeks. The beta is 0.82, so Syndax Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | -52.95% |
| 50-Day Moving Average | 12.52 |
| 200-Day Moving Average | 16.06 |
| Relative Strength Index (RSI) | 37.12 |
| Average Volume (20 Days) | 2,164,983 |
Income Statement
In the last 12 months, Syndax Pharmaceuticals had revenue of 23.68M
and earned -318.76M
in profits. Earnings per share was -3.73.
| Revenue | 23.68M |
| Gross Profit | 22.85M |
| Operating Income | -339.67M |
| Net Income | -318.76M |
| EBITDA | -313.82M |
| EBIT | -313.83M |
| Earnings Per Share (EPS) | -3.73 |
Full Income StatementBalance Sheet
The company has 154.08M in cash and 345.74M in
debt, giving a net cash position of -191.66M.
| Cash & Cash Equivalents | 154.08M |
| Total Debt | 345.74M |
| Net Cash | -191.66M |
| Retained Earnings | -1.22B |
| Total Assets | 640.71M |
| Working Capital | 454.2M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -274.9M
and capital expenditures 0, giving a free cash flow of -274.9M.
| Operating Cash Flow | -274.9M |
| Capital Expenditures | n/a |
| Free Cash Flow | -274.9M |
| FCF Per Share | -3.21 |
Full Cash Flow StatementMargins
Gross margin is 96.51%, with operating and profit margins of -1434.43% and -1346.11%.
| Gross Margin | 96.51% |
| Operating Margin | -1434.43% |
| Pretax Margin | -1346.11% |
| Profit Margin | -1346.11% |
| EBITDA Margin | -1325.26% |
| EBIT Margin | -1434.43% |
| FCF Margin | -1160.91% |
